Literature DB >> 11984700

Alendronate and pharmacological doses of 1alpha OHD3 therapy in a patient with McCune-Albright syndrome and accompanying hypophosphatemia.

Takehisa Yamamoto1, Keiichi Ozono, Masaaki Shima, Hideki Yoshikawa, Shintaro Okada.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 11984700     DOI： 10.1007/s007740200024

Source DB:  PubMed          Journal:  J Bone Miner Metab        ISSN： 0914-8779            Impact factor:   2.626


× No keyword cloud information.
  5 in total

1.  Oral Alendronate Treatment for Severe Polyostotic Fibrous Dysplasia due to McCune-Albright Syndrome in a Child: A Case Report.

Authors:  Ana Luiza Andrade Aragão; Ivani Novato Silva
Journal:  Int J Pediatr Endocrinol       Date:  2010-09-21

Review 2.  [Bisphosphonates in the therapy of fibrous dysplasia. Relevant data and practical aspects].

Authors:  Sigrun Egner-Höbarth; H Welkerling; R Windhager
Journal:  Orthopade       Date:  2007-02       Impact factor: 1.087

Review 3.  Clinical approach to clarifying the mechanism of abnormal bone metabolism in McCune-Albright syndrome.

Authors:  Takehisa Yamamoto
Journal:  J Bone Miner Metab       Date:  2006       Impact factor: 2.626

4.  Long-term efficacy of oral alendronate therapy in an elderly patient with polyostotic fibrous dysplasia: A case report.

Authors:  Gui-Dong Li; Akira Ogose; Tetsuo Hotta; Hiroyuki Kawashima; Takashi Ariizumi; Yongjun Xu; Naoto Endo
Journal:  Oncol Lett       Date:  2011-08-02       Impact factor: 2.967

Review 5.  Clinical and translational pharmacological aspects of the management of fibrous dysplasia of bone.

Authors:  Marlous Rotman; Neveen Agnes Therese Hamdy; Natasha M Appelman-Dijkstra
Journal:  Br J Clin Pharmacol       Date:  2018-12-25       Impact factor: 4.335
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.